<?xml version='1.0' encoding='utf-8'?>
<document id="31324935"><sentence text="Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects."><entity charOffset="28-39" id="DDI-PubMed.31324935.s1.e0" text="fluconazole" /><entity charOffset="68-79" id="DDI-PubMed.31324935.s1.e1" text="ruxolitinib" /><pair ddi="false" e1="DDI-PubMed.31324935.s1.e0" e2="DDI-PubMed.31324935.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31324935.s1.e0" e2="DDI-PubMed.31324935.s1.e1" /></sentence><sentence text="Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9"><entity charOffset="0-11" id="DDI-PubMed.31324935.s2.e0" text="Ruxolitinib" /></sentence><sentence text=" Dual inhibitors of these enzymes (like fluconazole) lead to increased ruxolitinib exposure relative to a single pathway inhibition of CYP3A4 or CYP2C9"><entity charOffset="40-51" id="DDI-PubMed.31324935.s3.e0" text="fluconazole" /><entity charOffset="71-82" id="DDI-PubMed.31324935.s3.e1" text="ruxolitinib" /><pair ddi="false" e1="DDI-PubMed.31324935.s3.e0" e2="DDI-PubMed.31324935.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31324935.s3.e0" e2="DDI-PubMed.31324935.s3.e1" /></sentence><sentence text=" The magnitude of this interaction, previously assessed via physiologically based pharmacokinetic (PBPK) models, was confirmed in an open-label, phase 1 study in healthy subjects" /><sentence text="" /><sentence text="The effect of multiple doses (200 mg) of fluconazole on single-dose (10 mg) PK of ruxolitinib was investigated including evaluation of the safety and tolerability"><entity charOffset="41-52" id="DDI-PubMed.31324935.s6.e0" text="fluconazole" /><entity charOffset="82-93" id="DDI-PubMed.31324935.s6.e1" text="ruxolitinib" /><pair ddi="false" e1="DDI-PubMed.31324935.s6.e0" e2="DDI-PubMed.31324935.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31324935.s6.e0" e2="DDI-PubMed.31324935.s6.e1" /></sentence><sentence text=" The PK parameters of ruxolitinib alone (reference) were compared to those of ruxolitinib combined with fluconazole (test)"><entity charOffset="22-33" id="DDI-PubMed.31324935.s7.e0" text="ruxolitinib" /><entity charOffset="78-89" id="DDI-PubMed.31324935.s7.e1" text="ruxolitinib" /><entity charOffset="104-115" id="DDI-PubMed.31324935.s7.e2" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.31324935.s7.e0" e2="DDI-PubMed.31324935.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31324935.s7.e0" e2="DDI-PubMed.31324935.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s7.e0" e2="DDI-PubMed.31324935.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31324935.s7.e1" e2="DDI-PubMed.31324935.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s7.e1" e2="DDI-PubMed.31324935.s7.e2" /></sentence><sentence text=" The point estimate and corresponding two-sided 90% confidence interval for the difference between means of test and reference parameters were determined" /><sentence text="" /><sentence text="All enrolled subjects (N = 15) completed the study" /><sentence text=" When coadministered with fluconazole, geometric means of ruxolitinib PK parameters Cmax, AUClast, and AUCinf increased by 47%, 234%, and 232%, respectively, vs ruxolitinib alone"><entity charOffset="26-37" id="DDI-PubMed.31324935.s11.e0" text="fluconazole" /><entity charOffset="58-69" id="DDI-PubMed.31324935.s11.e1" text="ruxolitinib" /><entity charOffset="161-172" id="DDI-PubMed.31324935.s11.e2" text="ruxolitinib" /><pair ddi="false" e1="DDI-PubMed.31324935.s11.e0" e2="DDI-PubMed.31324935.s11.e0" /><pair ddi="false" e1="DDI-PubMed.31324935.s11.e0" e2="DDI-PubMed.31324935.s11.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s11.e0" e2="DDI-PubMed.31324935.s11.e2" /><pair ddi="false" e1="DDI-PubMed.31324935.s11.e1" e2="DDI-PubMed.31324935.s11.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s11.e1" e2="DDI-PubMed.31324935.s11.e2" /></sentence><sentence text=" The median Tmax decreased slightly, apparent clearance decreased approximately threefold, and elimination half-life increased approximately 2" /><sentence text="5-fold, upon ruxolitinib administration with fluconazole vs ruxolitinib alone"><entity charOffset="13-24" id="DDI-PubMed.31324935.s13.e0" text="ruxolitinib" /><entity charOffset="45-56" id="DDI-PubMed.31324935.s13.e1" text="fluconazole" /><entity charOffset="60-71" id="DDI-PubMed.31324935.s13.e2" text="ruxolitinib" /><pair ddi="false" e1="DDI-PubMed.31324935.s13.e0" e2="DDI-PubMed.31324935.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31324935.s13.e0" e2="DDI-PubMed.31324935.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s13.e0" e2="DDI-PubMed.31324935.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31324935.s13.e1" e2="DDI-PubMed.31324935.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s13.e1" e2="DDI-PubMed.31324935.s13.e2" /></sentence><sentence text=" These results were consistent with the prospective predictions from a SimCYP PBPK model" /><sentence text=" Adverse events (AEs) were reported in six subjects (none were suspected to be related to ruxolitinib); no death or on-treatment serious AE was reported"><entity charOffset="90-101" id="DDI-PubMed.31324935.s15.e0" text="ruxolitinib" /></sentence><sentence text="" /><sentence text="Coadministration of ruxolitinib with fluconazole significantly increased ruxolitinib systemic exposure; however, no AEs were attributed to ruxolitinib"><entity charOffset="20-31" id="DDI-PubMed.31324935.s17.e0" text="ruxolitinib" /><entity charOffset="37-48" id="DDI-PubMed.31324935.s17.e1" text="fluconazole" /><entity charOffset="73-84" id="DDI-PubMed.31324935.s17.e2" text="ruxolitinib" /><entity charOffset="139-150" id="DDI-PubMed.31324935.s17.e3" text="ruxolitinib" /><pair ddi="false" e1="DDI-PubMed.31324935.s17.e0" e2="DDI-PubMed.31324935.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31324935.s17.e0" e2="DDI-PubMed.31324935.s17.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s17.e0" e2="DDI-PubMed.31324935.s17.e2" /><pair ddi="false" e1="DDI-PubMed.31324935.s17.e0" e2="DDI-PubMed.31324935.s17.e3" /><pair ddi="false" e1="DDI-PubMed.31324935.s17.e1" e2="DDI-PubMed.31324935.s17.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s17.e1" e2="DDI-PubMed.31324935.s17.e2" /><pair ddi="false" e1="DDI-PubMed.31324935.s17.e1" e2="DDI-PubMed.31324935.s17.e3" /><pair ddi="false" e1="DDI-PubMed.31324935.s17.e2" e2="DDI-PubMed.31324935.s17.e2" /><pair ddi="false" e1="DDI-PubMed.31324935.s17.e2" e2="DDI-PubMed.31324935.s17.e3" /></sentence><sentence text=" Concomitant use of ruxolitinib with fluconazole (dose ≤ 200 mg) may require dose reduction/modification of ruxolitinib"><entity charOffset="20-31" id="DDI-PubMed.31324935.s18.e0" text="ruxolitinib" /><entity charOffset="37-48" id="DDI-PubMed.31324935.s18.e1" text="fluconazole" /><entity charOffset="108-119" id="DDI-PubMed.31324935.s18.e2" text="ruxolitinib" /><pair ddi="false" e1="DDI-PubMed.31324935.s18.e0" e2="DDI-PubMed.31324935.s18.e0" /><pair ddi="false" e1="DDI-PubMed.31324935.s18.e0" e2="DDI-PubMed.31324935.s18.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s18.e0" e2="DDI-PubMed.31324935.s18.e2" /><pair ddi="false" e1="DDI-PubMed.31324935.s18.e1" e2="DDI-PubMed.31324935.s18.e1" /><pair ddi="false" e1="DDI-PubMed.31324935.s18.e1" e2="DDI-PubMed.31324935.s18.e2" /></sentence><sentence text="" /></document>